Katrina J. Church - 14 Mar 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Signature
/s/Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
14 Mar 2022
Net transactions value
-$1,850
Form type
4
Filing time
16 Mar 2023, 21:17:43 UTC
Next filing
08 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise +3,456 +138% 5,956 14 Mar 2023 Direct F1
transaction BVS Class A Common Stock Sale $1,850 -1,332 -22% $1.39 4,624 15 Mar 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Award $0 +13,823 $0.000000 13,823 14 Mar 2022 Class A Common Stock 13,823 Direct F1, F4
transaction BVS Restricted Stock Units Options Exercise $0 -3,456 -25% $0.000000 10,367 14 Mar 2022 Class A Common Stock 3,456 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 Reflects shares sold to cover taxes upon the vesting of the RSUs on March 14, 2023 pursuant to a standing 10b5-1 instruction.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.3692 to $1.423, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The original grant of 13,823 RSUs vest in four approximately equal annual installments beginning on March 14, 2023.